Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School Boston, MA, USA.
Front Oncol. 2012 Apr 12;2:35. doi: 10.3389/fonc.2012.00035. eCollection 2012.
The function of tumor suppressor VHL is compromised in the vast majority of clear cell renal cell carcinoma, and its mutations or loss of expression was causal for this disease. pVHL was found to be a substrate recognition subunit of an E3 ubiquitin ligase, and most of the tumor-derived mutations disrupt this function. pVHL was found to bind to the alpha subunits of hypoxia-inducible factor (HIF) and promote their ubiquitination and proteasomal degradation. Proline hydroxylation on key sites of HIFα provides the binding signal for pVHL E3 ligase complex. Beside HIFα, several other VHL targets have been identified, including activated epidermal growth factor receptor (EGFR), RNA polymerase II subunits RPB1 and hsRPB7, atypical protein kinase C (PKC), Sprouty2, β-adrenergic receptor II, and Myb-binding protein p160. HIFα is the most well studied substrate and has been proven to be critical for pVHL's tumor suppressor function, but the activated EGFR and PKC and other pVHL substrates might also be important for tumor growth and drug response. Their regulations by pVHL and their relevance to signaling and cancer are discussed.
抑癌基因 VHL 的功能在绝大多数透明细胞肾细胞癌中受到损害,其突变或表达缺失是导致这种疾病的原因。pVHL 被发现是一种 E3 泛素连接酶的底物识别亚单位,大多数肿瘤衍生的突变会破坏这种功能。pVHL 被发现与缺氧诱导因子 (HIF) 的α亚单位结合,并促进其泛素化和蛋白酶体降解。HIFα关键位点的脯氨酸羟化提供了与 pVHL E3 连接酶复合物的结合信号。除了 HIFα,还已经鉴定出其他几个 VHL 靶标,包括激活的表皮生长因子受体 (EGFR)、RNA 聚合酶 II 亚基 RPB1 和 hsRPB7、非典型蛋白激酶 C (PKC)、Sprouty2、β-肾上腺素能受体 II 和 Myb 结合蛋白 p160。HIFα是研究最充分的底物,已被证明对 pVHL 的肿瘤抑制功能至关重要,但激活的 EGFR 和 PKC 以及其他 pVHL 底物也可能对肿瘤生长和药物反应很重要。讨论了它们被 pVHL 调节及其与信号转导和癌症的相关性。